Cassava Sciences, Inc.

NASDAQ:SAVA

26.95 (USD) • At close November 8, 2024
Bedrijfsnaam Cassava Sciences, Inc.
Symbool SAVA
Munteenheid USD
Prijs 26.95
Beurswaarde 1,292,958,590
Dividendpercentage 0%
52-weken bereik 8.79 - 42.2
Industrie Biotechnology
Sector Healthcare
CEO Mr. Remi Barbier
Website https://www.cassavasciences.com

An error occurred while fetching data.

Over Cassava Sciences, Inc.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known

Vergelijkbare Aandelen

Silk Road Medical, Inc logo

Silk Road Medical, Inc

SILK

27.49 USD

Celularity Inc. logo

Celularity Inc.

CELU

3.55 USD

MannKind Corporation logo

MannKind Corporation

MNKD

7.345 USD

Veru Inc. logo

Veru Inc.

VERU

0.732 USD

Crinetics Pharmaceuticals, Inc. logo

Crinetics Pharmaceuticals, Inc.

CRNX

60.69 USD

Instil Bio, Inc. logo

Instil Bio, Inc.

TIL

30.84 USD

Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc.

ALLO

3.08 USD

SomaLogic, Inc. logo

SomaLogic, Inc.

SLGC

2.1 USD

Innoviva, Inc. logo

Innoviva, Inc.

INVA

20.18 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)